Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - Piper Sandler raised its price target on Corbus Pharmaceuticals (NASDAQ:CRBP) to $51.00 from $35.00 on Monday, while maintaining an Overweight rating on the stock. The company, currently valued at $236.77 million, has seen its shares surge 18.38% in the past week, with analysts maintaining a strong buy consensus. According to InvestingPro, the stock is trading near its 52-week high of $20.77.
The upgrade follows new data for Corbus’s CRB-701 drug, which showed strong efficacy in treating head and neck squamous cell carcinoma (HNSCC) and cervical cancers in heavily pre-treated patients, according to the research firm’s Phase 1/2 ESMO update. While the company maintains a strong financial health score according to InvestingPro analysis, with a current ratio of 9.21 indicating solid liquidity, investors should note the stock’s RSI suggests overbought conditions.
At the 3.6 mg/kg dose, CRB-701 demonstrated an objective response rate (ORR) of 48% in HNSCC patients and 38% in cervical cancer patients, outperforming competing treatments like Merus’s petosemtamab (36% ORR in HNSCC) and Tivdak (18% ORR in cervical cancer).
Piper Sandler highlighted CRB-701’s manageable safety profile as a key differentiator, noting lower rates of peripheral neuropathy (approximately 8%), adverse skin reactions (28%), and Grade 3 adverse events (36%) compared to other similar drugs.
Corbus plans to engage with the FDA in the fourth quarter of 2025 and initiate a registrational study in HNSCC by mid-2026, with combination therapy data with pembrolizumab expected in the second half of 2026. With analyst targets ranging from $28 to $55, InvestingPro subscribers can access 12 additional key insights about CRBP’s financial health and market momentum to make more informed investment decisions.
In other recent news, Corbus Pharmaceuticals Holdings Inc. reported promising results from its Phase 1/2 clinical study of CRB-701, a cancer treatment, at the European Society for Medical Oncology Congress. The study demonstrated strong objective response rates in multiple tumor types, with 47.6% in head and neck squamous cell carcinoma, 37.5% in cervical cancer, and 55.6% in urothelial cancer at a 3.6 mg/kg dose. Following these results, H.C. Wainwright reaffirmed its Buy rating for Corbus Pharmaceuticals, maintaining a price target of $40.00. Mizuho also reiterated its Outperform rating and $32.00 price target, citing potential upside to estimates based on the new data. Meanwhile, Oppenheimer adjusted its price target from $60.00 to $53.00 while maintaining an Outperform rating. Corbus Pharmaceuticals also announced receiving FDA Fast Track Designation for CRB-701, which targets Nectin-4 in treating recurrent or metastatic head and neck squamous cell carcinoma. This designation is specifically for patients who have previously undergone platinum-based chemotherapy and anti-PD(L)-1 therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.